Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target

Cantor Fitzgerald analyst Jennifer Kim initiates coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Overweight rating and a price target of $3.50.

The analyst comments: "We are assuming coverage of ProQR Therapeutics (PRQR) with an OW rating and a 12-month price target of $3.50. PRQR is a biotechnology company focused on developing RNA therapies. Following PRQR’s recent strategy update in April 2022 and the company’s 1Q22 earnings update on 5/5, we believe PRQR has made some difficult, but smart, moves that could prove to be rewarding, with an extended cash runway into 2025E and through several potential milestones. Key upcoming milestones include: 1) update on sepofarsen following regulatory feedback from the EMA and FDA on post-hoc findings from the ILLUMINATE trial, 3Q22/early 4Q22, 2) discuss and seek alignment with regulators for ultevursen’s ongoing Phase 2/3 SIRIUS trial, 3Q22, and 3) provide update on first targets for Axiomer platform in 2H22.

Our Take: We see under-appreciated value for the stock in two key areas: 1) select ophthalmology programs (e.g., ultevursen [QR-421a] for USH2A-mediated Usher syndrome and retinitis pigmentosa [RP), and 2) potential product pipeline and partnership opportunities from the company’s Axiomer RNA base-editing technology platform."

For an analyst ratings summary and ratings history on ProQR Therapeutics N.V. click here. For more ratings news on ProQR Therapeutics N.V. click here.

Shares of ProQR Therapeutics N.V. closed at $0.56 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• JPMorgan Upgrades Beach Energy Ltd (BPT:AU) (BEPTF) to Overweight
• Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance